-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMGS-001 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMGS-001 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMGS-001 in Metastatic Colorectal Cancer Drug Details: IMGS-001 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMGS-001 in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMGS-001 in Metastatic Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMGS-001 in Metastatic Ovarian Cancer Drug Details: IMGS-001 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMGS-001 in Metastatic Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMGS-001 in Metastatic Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMGS-001 in Metastatic Prostate Cancer Drug Details: IMGS-001 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMGS-001 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMGS-001 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMGS-001 in Triple-Negative Breast Cancer (TNBC) Drug Details: IMGS-001...
-
Company Insights
NewBioCorRx Inc Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our BioCorRx Inc Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. BioCorRx Inc (BioCorRx) is a healthcare solution provider that offers treatment for substance use and other related disorders. The company offers alcoholism and opioid addiction treatment programs for use in rehabilitation and treatment centers. It distributes and licenses the BioCorRx recovery program, a medication-assisted treatment (MAT) program that includes a counseling program coupled with its proprietary naltrexone implant. It also...
-
Company Insights
NewNestlé S.A. – Digital Transformation Strategies
Nestlé S.A. (Nestlé) is a food and beverages company, offering more than 2,000 branded products across 190 countries. The company classifies its business operations into six reportable segments: Zone Americas (AMS); Zone Europe, the Middle East, and North Africa (EMENA); Zone Asia, Oceania, and sub-Saharan Africa (AOA); Nestlé Waters; Nestlé Nutrition; and Other Business. The company's product portfolio includes baby foods, bottled water, cereals, chocolate and confectionery, coffee, culinary products, chilled and frozen foods, dairy products, drinks, nutritional products, and...
-
Company Insights
NewMitsubishi Chemical Group Corporation – Digital Transformation Strategies
Mitsubishi Chemical Group Corp (Mitsubishi Chemical), formerly Mitsubishi Chemical Holdings Corp, manufactures chemicals and specialty materials. Its products include industrial chemicals, basic petrochemicals, solvents, acrylonitrile & related products, film & sheet, molded products & components, synthetic paper, composite materials, battery materials, display materials, recording materials, imaging materials, semiconductor materials, acrylic fiber, acetate fiber, composite fiber, food ingredients, pharmaceuticals, commodity polymers, engineering plastics, high-performance polymers & raw materials, curable materials, carbon materials, industrial gases and water treatment materials. The company serves...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Spartalizumab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Spartalizumab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Spartalizumab in Acute Myelocytic Leukemia (AML,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Spartalizumab in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Spartalizumab in Myelodysplastic Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Spartalizumab in Myelodysplastic Syndrome Drug Details: Spartalizumab (PDR-001) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Spartalizumab in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Spartalizumab in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Spartalizumab in Refractory Acute Myeloid Leukemia Drug Details: Spartalizumab...